INTELLIA THERAPEUTICS INC (NTLA) Stock Analyst Ratings
NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 81% to NTLA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 36.54. This target is 236.49% above the current price.
NTLA was analyzed by 34 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about NTLA.
In the previous month the buy percentage consensus was at a similar level.
NTLA was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-03 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-19 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-05-12 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-04-21 | Wolfe Research | Upgrade | Peer Perform -> Outperform |
| 2025-03-05 | HC Wainwright & Co. | Initiate | Buy |
| 2025-03-04 | Truist Securities | Maintains | Buy -> Buy |
| 2025-02-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-28 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-02-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-02-28 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-01-27 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-01-14 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-01-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-01-10 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-01-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-19 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-18 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-11-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-11 | Oppenheimer | Maintains | Outperform -> Outperform |